3 months in and triple agonist is still the thing I get wrong
Reporting in. 3 months in and triple agonist is still the thing I get wrong.
The numbers the title promised, since a headline without them is worthless: 3 months. Everything below is context for those.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Standing reminder in every thread here: unapproved compound, research material is not for human use, nothing on this board is medical advice.
Is that the 48-week figure or an earlier readout?
the escalation is where most of the reported trouble sits
This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.
Standing reminder in every thread here: unapproved compound, research material is not for human use, nothing on this board is medical advice.
This is the sentence the rest of the board should read first. Phase 2 is not a label.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
the phase 2 numbers were striking and they were also 48 weeks in a small population
It is a triple agonist at the GLP-1, GIP and glucagon receptors.
fabio_lehtinen is right about the escalation being the variable. It explains most of the difficult reports here.
not approved anywhere, which is the single most important fact in this board
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
the TRIUMPH programme is still running, so anything definitive is premature
The thing that surprised me was how much of the discussion here is inference rather than measurement.
Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.
Same read.
Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.
Which phase 2 arm are you quoting, and at what week?
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.
Are you comparing against phase 3 numbers for something else? They are not comparable.
phase 2 data only, and people quote it like it is a label
Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.
- 1Phase 2 estimates effect and finds a dose range. Phase 3 estimates it…8 comments in this branch · started by u/jarno_cabrera
- 2Standing reminder in every thread here: unapproved compound, research…7 comments in this branch · started by u/incretin_ivy